Introduction
Qure.ai is a Mumbai-based health technology company founded in 2016 that applies deep learning to medical imaging so clinicians can identify and triage diseases faster across lung cancer, tuberculosis, stroke, and other conditions. Prashant Warier serves as founder and chief executive officer, per Qure.ai’s about page. The company positions equitable healthcare as its mission — deploying FDA-cleared and CE-certified algorithms in more than 100 countries rather than limiting AI assistance to a handful of academic centers.
For Brel readers evaluating radiology AI, Qure.ai is distinctive for regulatory breadth: its about page cites multiple FDA clearances across brain CT and chest imaging, and a February 26, 2026 announcement added six new indications for qXR-Detect on chest X-ray, bringing total FDA-cleared indications to 26 across nine products.
What the company does
Qure.ai builds radiology AI that integrates into hospital workflows — flagging critical brain CT findings for triage, detecting and quantifying lung nodules, and providing computer-assisted detection on chest radiographs used in emergency departments and primary care. Products include qER for neurocritical head CT, qXR family algorithms for chest X-ray, and qCT LN Quant for lung nodule measurement on CT. Algorithms are designed as assistive tools: radiologists and clinicians retain interpretive authority while AI highlights findings and structures measurements.
Who it serves
Qure.ai serves hospital networks, radiology practices, public-health tuberculosis programs, and life-sciences partners running imaging-enriched trials. North American expansion is led by an executive sales organization referenced on its about page, while global health deployments include WHO-endorsed chest X-ray TB screening workflows cited in the company’s journey timeline. Buyers typically evaluate Qure.ai on regulatory clearance depth, integration with PACS and triage queues, and performance across diverse patient populations validated in FDA submission studies.
Company background
Qure.ai was founded in 2016 in Mumbai by Prashant Warier and has grown through a sequence of regulatory milestones — early CE certification for brain CT, Lancet-featured research in 2018, and expanding FDA clearances through the 2020s. The company raised venture funding including a 2020 Series A from Sequoia Capital and MassMutual Ventures noted on its about timeline, and has received recognition including TIME100 Most Influential Companies in 2025. Warier remains the public executive face as founder and CEO.
Product and AI capabilities
Qure.ai’s models apply convolutional deep learning to DICOM images, producing triage notifications, bounding-box localization, and quantitative measurements validated in standalone and multi-reader multi-case studies for FDA submissions. qXR-Detect, cleared February 26, 2026, categorizes chest X-ray findings across six regions of interest — lung, pleura, mediastinum and heart, bone, hardware, and other structures — and is described by Qure.ai as the only chest X-ray CADe device cleared with a Predetermined Change Control Plan, allowing algorithm updates under FDA oversight.
Chest radiography remains the highest-volume imaging study in U.S. emergency care; Qure.ai cites roughly 70 million chest X-rays annually in its FDA announcement. Triage algorithms for intracranial hemorrhage on head CT address a different acute pathway, while lung nodule quantification on CT supports oncology surveillance that may begin with incidental findings on X-ray in low screening-uptake regions.
Key developments
2016: Qure.ai founded in Mumbai. 2020: Qure.ai reports comprehensive FDA clearance for brain CT product and launches COVID-19 AI solution. February 26, 2026: FDA clears qXR-Detect with six new chest X-ray indications; total FDA-cleared indications reach 26 across nine X-ray and CT products per Qure.ai press coverage.
Professor Amit Gupta of University Hospitals Cleveland Medical Center is quoted in the February 2026 release on explainability features — bounding boxes and region labels — that help radiologists understand why alerts fire, addressing a common hospital concern about black-box triage tools.
Why it matters
Qure.ai matters because radiology AI procurement often collapses into vendor marketing claims about sensitivity without comparable regulatory labels. Qure.ai’s published clearance count gives hospital committees a countable benchmark. Its global TB and lung cancer screening footprint also shows how imaging AI moves beyond tertiary radiology into public-health scale deployments — a different buying motion than U.S.-only CAD vendors such as Viz.ai in care coordination.
Predetermined Change Control Plans matter for enterprise buyers planning multi-year contracts: hospitals want assurance that algorithm improvements can deploy without repeating full procurement cycles. Qure.ai’s chief medical officer Samir Shah, MD, FACR, is named in the February 2026 release as a credible clinical voice for radiology committee review.
Sector context
Qure.ai belongs in Brel’s AI in healthcare coverage under medical imaging, related to Viz.ai and digital pathology players such as PathAI. Readers comparing triage versus detection products should note Qure.ai’s chest X-ray CADe focus versus neurovascular alert routing — overlapping AI discipline, different clinical workflows.
Global deployment in 105+ countries cited on Qure.ai’s about page distinguishes Qure from U.S.-centric imaging AI vendors — regulatory breadth across FDA, CE, and WHO endorsements matters for ministries of health and NGO procurement committees, not only U.S. hospital PACS committees.
Sources and references
Qure.ai about page, company website, and February 26, 2026 qXR-Detect FDA clearance announcement.
- Qure.ai — About Us (qure.ai)
- Qure.ai — qXR-Detect FDA clearances (qure.ai, February 26, 2026)
- Qure.ai — Company website (qure.ai)
Reviewed July 10, 2026. Prashant Warier is founder and CEO per about-us.